NeuroSense Therapeutics Ltd.
NRSNNeuroSense Therapeutics reported modestly narrower losses in FY2025 amid sustained R&D investment in PrimeC for ALS, with operating cash burn improving due to tighter expense control while advancing toward Phase 3 following positive PARADIGM biomarker data.
NASDAQ
Healthcare
Biotechnology
$0.83
+0.07(9.2%)
52W $0.71 – $2.49
Quick: